Diagnosis, Treatment, and Prevention of Colorectal Cancer Amid Abnormal Lipid Metabolism
Launched by TIANJIN UNION MEDICAL CENTER · Mar 19, 2025
Trial Information
Current as of April 30, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how certain fats in the body, inflammation, and colorectal cancer (CRC) are connected. Researchers are creating a detailed database of CRC patients that includes information about their health, body measurements, imaging tests, and specific markers related to fat metabolism and inflammation. The main goal is to discover how these factors influence the development and progression of CRC and to improve patient care through a personalized prevention strategy. This strategy will involve predicting risks early, offering targeted treatments, and providing comprehensive support after surgery.
To be eligible for the trial, participants should be between 20 and 80 years old and have a confirmed diagnosis of colorectal cancer. They will need to give their consent to join the study. Unfortunately, individuals under 20 or over 80, those who cannot perform daily activities, or those with certain infectious diseases cannot participate. If you join the study, you can expect to contribute valuable information that may help improve CRC treatment and prevention in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 20-80 years, confirmed CRC diagnosis, consent to participate in the study.
- Exclusion Criteria:
- • Age \<20 or \>80 years; inability to perform activities of daily living; presence of infectious diseases; lack of communication and cognitive abilities; refusal to participate in the study.
About Tianjin Union Medical Center
Tianjin Union Medical Center is a leading healthcare institution based in Tianjin, China, dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the center integrates cutting-edge technology and expert medical practices to conduct rigorous clinical studies across various therapeutic areas. Committed to ethical standards and patient safety, Tianjin Union Medical Center aims to contribute to the global medical community by facilitating the development of new treatments and enhancing the understanding of complex health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jing Xu, PhD
Principal Investigator
Tianjin Union Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported